Actonel With Calcium (copackaged) is a drug owned by Warner Chilcott Co Llc. It is protected by 12 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 14, 2019. Details of Actonel With Calcium (copackaged)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6465443 (Pediatric) | Method for inhibiting bone resorption |
Feb, 2019
(5 years ago) |
Expired
|
|
US6015801 (Pediatric) | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) |
Expired
|
|
US5994329 (Pediatric) | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) |
Expired
|
|
US6432932 (Pediatric) | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) |
Expired
|
|
US6165513 (Pediatric) | Film-coated tablet for improved upper gastrointestinal tract safety |
Dec, 2018
(5 years ago) |
Expired
|
| US6465443 | Method for inhibiting bone resorption |
Aug, 2018
(6 years ago) |
Expired
|
| US5994329 | Method for inhibiting bone resorption |
Jul, 2018
(6 years ago) |
Expired
|
| US6432932 | Method for inhibiting bone resorption |
Jul, 2018
(6 years ago) |
Expired
|
| US6015801 | Method for inhibiting bone resorption |
Jul, 2018
(6 years ago) |
Expired
|
| US6165513 | Film-coated tablet for improved upper gastrointestinal tract safety |
Jun, 2018
(6 years ago) |
Expired
|
|
US5583122 (Pediatric) | Pharmaceutical compositions containing geminal diphosphonates |
Jun, 2014
(10 years ago) |
Expired
|
| US5583122 | Pharmaceutical compositions containing geminal diphosphonates |
Dec, 2013
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Actonel With Calcium (copackaged)'s patents.
Latest Legal Activities on Actonel With Calcium (copackaged)'s Patents
Given below is the list of recent legal activities going on the following patents of Actonel With Calcium (copackaged).
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 15 Oct, 2002 | US6465443 |
| Patent Issue Date Used in PTA Calculation Critical | 15 Oct, 2002 | US6465443 |
| Issue Notification Mailed Critical | 27 Sep, 2002 | US6465443 |
| Receipt into Pubs | 13 Sep, 2002 | US6465443 |
| Receipt into Pubs | 29 Aug, 2002 | US6465443 |
| Application Is Considered Ready for Issue Critical | 22 Aug, 2002 | US6465443 |
| Workflow - Power of Attorney - Begin | 21 Aug, 2002 | US6465443 |
| Issue Fee Payment Received Critical | 21 Aug, 2002 | US6465443 |
| Issue Fee Payment Verified Critical | 21 Aug, 2002 | US6465443 |
| Workflow - Power of Attorney - Finish | 20 Aug, 2002 | US6465443 |
US patents provide insights into the exclusivity only within the United States, but Actonel With Calcium (copackaged) is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Actonel With Calcium (copackaged)'s family patents as well as insights into ongoing legal events on those patents.
Actonel With Calcium (copackaged)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Actonel With Calcium (copackaged)'s generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 14, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Actonel With Calcium (copackaged) Generics:
There are no approved generic versions for Actonel With Calcium (copackaged) as of now.
Alternative Brands for Actonel With Calcium (copackaged)
Actonel With Calcium (copackaged) which is used for preventing and treating osteoporosis in postmenopausal women., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Apil |
| |||
About Actonel With Calcium (copackaged)
Actonel With Calcium (Copackaged) is a drug owned by Warner Chilcott Co Llc. It is used for preventing and treating osteoporosis in postmenopausal women. Actonel With Calcium (Copackaged) uses Calcium Carbonate; Risedronate Sodium as an active ingredient. Actonel With Calcium (Copackaged) was launched by Warner Chilcott in 2005.
Approval Date:
Actonel With Calcium (copackaged) was approved by FDA for market use on 12 August, 2005.
Active Ingredient:
Actonel With Calcium (copackaged) uses Calcium Carbonate; Risedronate Sodium as the active ingredient. Check out other Drugs and Companies using Calcium Carbonate; Risedronate Sodium ingredient
Treatment:
Actonel With Calcium (copackaged) is used for preventing and treating osteoporosis in postmenopausal women.
Dosage:
Actonel With Calcium (copackaged) is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 500MG BASE;35MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |